The HPV vaccine is a critical tool in the fight against cervical cancer, which is the fourth most common cancer among women globally, resulting in approximately 600,000 new cases and 340,000 deaths each year. The stakes are high, particularly for women in lower-income countries, who are three times more likely to develop cervical cancer and six times more likely to die from it compared to those in wealthier nations. The introduction and widespread adoption of the HPV vaccine could significantly reduce these alarming statistics.
HPV vaccination typically occurs during adolescence, a time when routine pediatric visits are less common. This gap in healthcare access can hinder vaccination efforts, making it vital for public health initiatives to adapt their strategies. Organizations like PATH have collaborated with immunization program managers to assess the operational context and estimate the ongoing costs associated with HPV vaccine delivery. Their research has provided valuable insights into implementing a two-dose HPV vaccination schedule across six countries: Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda.
In line with global health initiatives, the World Health Organization (WHO) has established the 90-70-90 targets for 2030, aiming to eliminate cervical cancer as a public health threat. One of these targets is to ensure that 90% of girls are vaccinated against HPV by the age of 15. Rwanda stands out as a success story, having achieved vaccination coverage close to 98%. This achievement underscores the potential for effective vaccination programs to drastically reduce the incidence of cervical cancer.
More than 90% of cervical cancer deaths occur in low- and middle-income countries, highlighting the urgent need for equitable access to vaccination and screening. The first World Cervical Cancer Elimination Day was observed in November 2025, marking a significant milestone in the global health agenda. Experts emphasize that “Cervical cancer should no longer be killing women,” pointing to the preventable nature of the disease and the importance of early detection and treatment.
Despite the progress made, challenges remain. The tragedy of cervical cancer is not just in its prevalence but also in the inequalities that underpin it. Women in lower-income regions often lack access to necessary healthcare services, including vaccinations and screenings. As a result, cervical cancer elimination must become a financing priority to ensure that all women, regardless of their socio-economic status, have the opportunity to protect themselves.
The WHO’s targets for 2030 also include ensuring that 90% of women are screened by age 35 and again by age 45, as well as treating 90% of women with cervical disease. Achieving these goals will require concerted efforts from governments, health organizations, and communities to prioritize cervical cancer prevention and treatment.
As the global community rallies to combat cervical cancer, the tools are available, and the window for action is open. However, the path forward is fraught with uncertainties regarding funding, healthcare infrastructure, and public awareness. Continued advocacy and investment in HPV vaccination programs are essential to realize the vision of a world where cervical cancer is no longer a public health threat.
